Compounders Research Compare

Pharvaris N.V.(PHVS)

Biotechnology · Zug, ZH

$30.88+0.39 (+1.28%)

Delayed quote: Oct 6, 2026, 2:40 PM EDT

About Pharvaris N.V.

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Zug, ZH

148 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Berndt Modig

View full financials

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T18:42:49.594Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:42:49.594Z.

Quote observation: 2026-10-06T18:40:09.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 2,157,885,939
Total debt · period ending 2026-06-30: 769,518.64704
Cash · period ending 2026-06-30: 363,535,334.76
TTM operating income · period ending 2026-06-30: -212,448,886.02453

FMP input reference: 2e72a758e634708c28c06ae15f1e09243225437df43ff658102191b35b06d910

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

PHVS EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

PHVS Competitors' EV/EBIT Ratio

Pharvaris N.V.

Current

Market Cap

$2.16B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GeneDx Holdings Corp.

Market Cap

$2.13B

EV/EBIT Ratio

N/A

TTM Avg

501.30x

3Y Avg

501.30x

5Y Avg

501.30x

SELLAS Life Sciences Group, Inc.

Market Cap

$2.13B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Addus HomeCare Corporation

Market Cap

$2.11B

EV/EBIT Ratio

14.31x

TTM Avg

15.46x

3Y Avg

18.22x

5Y Avg

20.56x

Maravai LifeSciences Holdings, Inc.

Market Cap

$2.21B

EV/EBIT Ratio

24.14x

TTM Avg

17.43x

3Y Avg

12.93x

5Y Avg

8.03x

Vera Therapeutics, Inc.

Market Cap

$2.09B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Viridian Therapeutics, Inc.

Market Cap

$2.07B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Vericel Corporation

Market Cap

$2.07B

EV/EBIT Ratio

111.89x

TTM Avg

307.23x

3Y Avg

485.43x

5Y Avg

1367.82x

Celldex Therapeutics, Inc.

Market Cap

$2.07B

EV/EBIT Ratio

N/A

TTM Avg

4584.86x

3Y Avg

4584.86x

5Y Avg

4584.86x

Alvotech

Market Cap

$2.07B

EV/EBIT Ratio

71.32x

TTM Avg

53.16x

3Y Avg

49.42x

5Y Avg

49.42x

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Pharvaris N.V. (PHVS)	$2.16B	N/A	N/A	N/A	N/A
GeneDx Holdings Corp. (WGS)vs ›	$2.13B	N/A	501.30x	501.30x	501.30x
SELLAS Life Sciences Group, Inc. (SLS)vs ›	$2.13B	N/A	N/A	N/A	N/A
Addus HomeCare Corporation (ADUS)vs ›	$2.11B	14.31x	15.46x	18.22x	20.56x
Maravai LifeSciences Holdings, Inc. (MRVI)vs ›	$2.21B	24.14x	17.43x	12.93x	8.03x
Vera Therapeutics, Inc. (VERA)vs ›	$2.09B	N/A	N/A	N/A	N/A
Viridian Therapeutics, Inc. (VRDN)vs ›	$2.07B	N/A	N/A	N/A	N/A
Vericel Corporation (VCEL)vs ›	$2.07B	111.89x	307.23x	485.43x	1367.82x
Celldex Therapeutics, Inc. (CLDX)vs ›	$2.07B	N/A	4584.86x	4584.86x	4584.86x
Alvotech (ALVO)vs ›	$2.07B	71.32x	53.16x	49.42x	49.42x

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA EV/Sales Operating Income All Metrics